The U.S. rheumatoid arthritis (RA) market is crowded, with the availability of nine different biologics and Xeljanz, representing six distinct drug classes. With the impending entry of biosimilars and emerging therapies (Jak and IL-6 inhibitors), marketers will be faced with increased challenges to gain favorable formulary positioning and physician uptake. Rheumatoid Arthritis | Access & Reimbursement | US examines the prescribing and reimbursement environment for current and emerging RA agents, according to surveyed rheumatologists and managed care organization (MCO) pharmacy directors and medical directors. This content explores stakeholder perspectives that affect prescribing and reimbursement of key RA agents and dynamics that will promote or restrict market access and uptake of emerging RA therapies.


Related Reports

Rheumatoid Arthritis | Landscape & Forecast | Disease Landscape & Forecast

The increasingly crowded RA market boasts many different targeted agents representing several distinct drug classes, including blockbuster

View Details

Rheumatoid Arthritis | Access & Reimbursement | Detailed, Expanded Analysis (US)

MARKET OUTLOOK The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, together with conventional treatments...

View Details

Rheumatoid Arthritis | Emerging Therapies | Olumiant (Baricitinib) Launch Tracking Wave 3

Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years after the launch of Pfizer’s Jak inhibito...

View Details

Rheumatoid Arthritis | Epidemiology | Emerging Markets

DRG Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key p...

View Details